Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder.
BACKGROUND
This study extends an initial finding of increased levels of apoE in Brodmann's area (BA) 9 from subjects with schizophrenia to determine if apoE is altered in other brain regions and in brains from subjects with bipolar I disorder (BID).


METHODS
ApoE was quantified apoE in BA 9, 10, 40, 46 and caudate putamen from control (n = 18), schizophrenic (n = 19) and BID (n = 8) subjects using Western blotting.


RESULTS
In schizophrenia, there was increased apoE in BA9 (mean +/- SEM: schizophrenia 3.8 +/- .18 vs. control 3.2 +/- .19) and BA46 (schizophrenia 2.7 +/- .26 vs. control 1.6 +/- .20). In BID, increased levels of the apolipoprotein were detected in the caudate putamen (BID 3.3 +/- .44 vs. control 2.4 +/- .19) and BA9 (BID 4.0 +/- .27 vs. control 3.2 +/- .19) with a decrease in apoE being measured in BA10 (BID 1.6 +/- .16 vs. control 3.9 +/- .53).


CONCLUSIONS
This study has shown disease specific, regionally discrete changes in levels of apoE in brain obtained post mortem from schizophrenic and BID subjects. Our data adds weight to the hypothesis that changes in the levels of apolipoproteins may be involved in the pathologies of schizophrenia and bipolar disorder.
Digney
Alison
A
Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia.
Keriakous
Dahlia
D
Scarr
Elizabeth
E
Thomas
Elizabeth
E
Dean
Brian
B
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001057:Apolipoproteins E / Q000378:metabolism*; D001714:Bipolar Disorder / Q000378:metabolism*; D015153:Blotting, Western / Q000379:methods; D001923:Brain Chemistry / Q000502:physiology; D002540:Cerebral Cortex / Q000033:anatomy & histology / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017072:Neostriatum / Q000378:metabolism*; D011180:Postmortem Changes; D012559:Schizophrenia / Q000378:metabolism*
D001057:Apolipoproteins E